MacroGenics, Inc. Announces Pricing Of Public Offering Of Common Stock

ROCKVILLE, Md., Feb. 12, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price of $36.50 per share, before underwriting discounts. MacroGenics is selling 1,800,000 shares of its common stock in this offering, and certain stockholders are selling 1,200,000 shares of common stock in this offering. MacroGenics will not receive any proceeds from the sale of shares by the selling stockholders. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock, if any, at the public offering price, less the underwriting discount.

Help employers find you! Check out all the jobs and post your resume.